Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Neuroscience Right
  3. Reyvow (lasmiditan) tablets CV Right
  4. How is Reyvow® (lasmiditan) metabolized and eliminated?
Search Reyvow (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Reyvow ® (lasmiditan) tablets CV

50 mg, 100 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How is Reyvow® (lasmiditan) metabolized and eliminated?

Reyvow (lasmiditan) undergoes hepatic and extrahepatic metabolism primarily by non-cytochrome P450 enzymes. Recovery of unchanged lasmiditan in urine was low and accounted for approximately 3% of the dose.

US_cFAQ_LAS004_METABOLISM_ELIMINATION
US_cFAQ_LAS004_METABOLISM_ELIMINATION
en-US

Pharmacokinetic Properties

Metabolism

Lasmiditan undergoes hepatic and extrahepatic metabolism primarily by non-cytochrome P450 enzymes.1

The following enzymes are not involved in metabolism of lasmiditan, including

  • monoamine oxidase-A
  • monoamine oxidase-B
  • flavin monooxygenase 3
  • cytochrome P450 reductase
  • xanthine oxidase
  • alcohol dehydrogenase
  • aldehyde dehydrogenase, and
  • aldo-keto reductases.1

Major metabolites of lasmiditan identified in plasma and urine are

  • S-M8, through ketone reduction to alcohol (major pathway)
  • M7, through oxidation on piperidine ring, and
  • M18, through a combination of M7 and M8 pathways.1

Relative to lasmiditan, these metabolites are considered pharmacologically inactive.1

Excretion

Lasmiditan is primarily eliminated via metabolism.1

Renal excretion is a minor route of lasmiditan clearance with approximately 3% of the dose recovered as unchanged lasmiditan in urine. Metabolite S-M8 represented approximately 66% of the dose in urine, with the majority of recovery within 48 hours post dose.1

Enclosed Prescribing Information

REYVOW® (lasmiditan) tablets, for oral use, CV, Lilly

Reference

1Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: August 12, 2021

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly